| Literature DB >> 32180928 |
Puja Saha1, Deepanjan Panda1, Diana Müller2, Arunabha Maity1, Harald Schwalbe2, Jyotirmayee Dash1.
Abstract
Non-canonical DNA i-motifs and G-quadruplexes are postulated as genetic switches for the transcriptional regulation of proto-oncogenes. However, in comparison to G-quadruplexes, the therapeutic potential of i-motifs is less explored. The development of i-motif selective ligands by conventional approaches is challenging due to the structural complexity of i-motifs. The target guided synthetic (TGS) approach involving in situ cycloaddition could provide specific ligands for these dynamic DNA structures. Herein, we have used i-motif forming C-rich DNA and their complementary G-quadruplex forming DNA sequences of c-MYC and BCL2 promoter regions as well as a control self-complementary duplex DNA sequence as the templates to generate selective ligands from a pool of reactive azide-alkyne building blocks. In our approach, thiolated DNA targets are immobilized on the surface of gold-coated iron nanoparticles to enable efficient isolation of the newly generated ligands from the solution mixture by simple magnetic decantation. The combinatorial in situ cycloaddition generated cell-membrane permeable triazole leads for respective DNA targets (c-MYC and BCL2 i-motifs and G-quadruplexes) that selectively promote their formation. In vitro cellular studies reveal that the c-MYC i-motif and G-quadruplex leads downregulate c-MYC gene expression whereas the BCL2 i-motif lead upregulates and the BCL2 G-quadruplex lead represses BCL2 gene expression. The TGS strategy using i-motif DNA nanotemplates represents a promising platform for the direct in situ formation of i-motif specific ligands for therapeutic intervention. This journal is © The Royal Society of Chemistry 2020.Entities:
Year: 2020 PMID: 32180928 PMCID: PMC7047845 DOI: 10.1039/d0sc00514b
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1DNA functionalized nanotemplates; i-motifs (c-MYC and BCL2), G-quadruplexes (c-MYC and BCL2), double and C-rich single stranded DNA (dsDNA and ssDNA) functionalized gold coated magnetic nanoparticles.
Fig. 2Characterization of i-motif DNA linked magnetic nanoparticles (C4·Au@Fe3O4 NPs). (a and b) UV-Vis absorption spectra of c-MYC C4·Au@Fe3O4 and BCL2 C4·Au@Fe3O4 NPs at 25 °C; (c and d) TEM images of c-MYC and BCL2 i-motif functionalized Au@Fe3O4 NPs (scale bar 50 nm); (e and f) CD spectra of c-MYC C4·Au@Fe3O4 and BCL2 C4·Au@Fe3O4 NPs; buffer: 10 mM sodium cacodylate, pH 5.5.
Fig. 3Alkyne (1a–d) and azide (2a–q) fragments and regioisomeric 1,4-anti (3aa–3dq) and 1,5-syn (3aa–3dq) triazoles derived from combinations of alkyne and azide building blocks.
Fig. 4Schematic representation of the target guided synthetic approach using i-motif magnetic nanotemplates (c-MYC C4·Au@Fe3O4 & BCL2 C4·Au@Fe3O4) for in situ formation of potent binders.
Fig. 5The hit compounds formed using (a) c-MYC and (b) BCL2 C4·Au@Fe3O4 templates. The selective lead compounds are highlighted. HPLC chromatograms of the products obtained (c and d) with c-MYC C4·Au@Fe3O4 and (e) with BCL2 C4·Au@Fe3O4.
Fig. 6The hit compounds formed using (a) c-MYC and (b) BCL2 G4·Au@Fe3O4 templates. The selective lead compounds are highlighted.
Fig. 7Triazole leads formed via in situ cycloaddition promoted by DNA nanotemplates.
Stabilization potentials (ΔTm) and apparent dissociation constants [Kd(app)] of lead triazole ligands for i-motif (C4), G-quadruplexe (G4) and dsDNA as determined by the FRET based DNA melting assay and fluorescence spectroscopic titrations
| Δ |
| |||||||
|
|
|
|
|
|
|
|
| |
|
| 29.7 | 2.9 | 6.4 | 2.1 | 0.25 | ns | 1.61 | 1.83 |
|
| 12.7 | 18.6 | 3.5 | 0.4 | 1.18 | 0.66 | 1.63 | 2.01 |
|
| 3.7 | 1.6 | 19.3 | 5.7 | 1.59 | ns | 0.17 | 1.62 |
|
| 1.8 | 1 | 7.7 | 11.8 | 2.21 | ns | 0.91 | 0.68 |
|
| 0.2 | 0.6 | 0.9 | 0.5 | ns | ns | ns | ns |
T m for c-MYC C4, 47.2 °C.
T m for BCL2 C4, 44.0 °C.
T m for c-MYC G4, 68.3 °C.
T m for BCL2 G4, 72.1 °C.
T m for dsDNA, 63.4 °C. Buffer used for FRET melting studies; i-motif (C4) DNA: 10 mM sodium cacodylate buffer (pH 5.5), G-quadruplex (G4) and dsDNA: 60 mM potassium cacodylate buffer (pH 7.4).
ns: Kd(app) could not be determined due to non-significant changes in fluorescence intensity upon addition of DNA. Experiments were performed in triplicate and the average values are provided.
Fig. 8(a–d) Fluorescence spectroscopic titrations of lead ligands (1 μM) with c-MYC C4,BCL2 C4, c-MYC G4 and BCL2 G4 DNA. (e–h) Fluorescence response curves of 3be, 3bm, 3ao and 3ap with incremental addition of c-MYC C4 (blue), BCL2 C4 (orange), c-MYC G4 (purple), BCL2 G4 (green) and dsDNA (light blue).
IC50 values of lead compounds in human cancer cells and normal cells as measured using the XTT assay after 24 h of treatment
| IC50 (μM) | ||||
| Ligands | HeLa | A549 | B95.8 | NKE |
|
| 1.0 | 4.2 | 4.5 | 13.6 |
|
| >50.0 | >20.0 | >50.0 | >25.0 |
|
| 1.9 | 3.0 | 4.9 | 25.0 |
|
| 7.9 | 14.9 | 8.9 | >25.0 |
Three individual experiments were performed and the average values are presented.
Fig. 9(a–d) qRT-PCR and western blotting analysis results of c-MYC and BCL2 gene expression in HeLa and B95.8 cells after 24 h of treatment with 3be, 3bm, 3ao and 3ap. The in vitro dual luciferase promoter assay for evaluating the effect of the lead ligands on the promoter activity of (e) the c-MYC-FLuc promoter and (f) BCL2-FLuc promoter [*p value is < 0.05].
Fig. 10Proposed model for targeting four-stranded DNA secondary structures within the c-MYC and BCL2 gene promoter regions.